Tauriga Sciences to Report Important and Material Progress in Development of its Pharmaceutical Grade Version of Tauri-Gum
June 05 2020 - 10:06AM
InvestorsHub NewsWire
Tauriga Sciences Inc. to Report Important and
Material Progress in the Development of its Pharmaceutical Grade
Version of Tauri-Gum
The Company’s Proposed
Pharmaceutical Grade Version of Tauri-Gum™ is Being Developed for
Nausea Regulation, Intended Specifically to Target: Patients
Subjected to Ongoing Chemotherapy Treatment(s) (the
“Indication”)
NEW YORK, NY -- June
5, 2020 -- InvestorsHub NewsWire -- Tauriga Sciences, Inc.
(OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences Company, with proprietary CBD & CBG infused
chewing gums and edibles product(s) as well as two ongoing
Biotechnology initiatives, today announced that, over the course of
the next week, the Company will report important and material
progress in the development of its Pharmaceutical Grade version of
Tauri-Gum™. The Company has been working with great
diligence, over the past weeks, to advance through the preliminary
stages of the drug development process. The delivery
system for this Pharmaceutical product is an improved version of
the existing “Tauri-Gum™” chewing gum formulation based on
continued research and development.
On March 18, 2020 the
Company announced that it had filed a Provisional U.S. Patent
covering its Pharmaceutical grade version of Tauri-Gum™. This
patent application, filed with the United States Patent &
Trademark Office (“U.S.P.T.O.”), is titled: “MEDICATED CBD
COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF
TREATMENT.”
U.S. Provisional
Patent Application No. 62/990,709
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc.
(TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavors: Peach-Lemon and Black Currant). The
Company’s commercialization strategy consists of a broad array of
retail customers, distributors, and a fast-growing E-Commerce
business segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complementary to the
Company’s retail business, are its two ongoing biotechnology
initiatives. The first one relates to the development of a
Pharmaceutical grade version of Tauri-Gum™, for nausea regulation
(specifically designed to help patients that are subjected to
ongoing chemotherapy treatment). On March 18, 2020, the
Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration
agreement with Aegea Biotechnologies Inc. for the co-development of
a rapid, multiplexed, Novel Coronavirus (COVID-19) test with
superior sensitivity and
selectivity.
The Company is
headquartered in New York City and operates a regional office in
Barcelona, Spain. In addition, the Company operates a full
time E-Commerce fulfillment center located in LaGrangeville, New
York.
DISCLAIMER --
Forward-Looking Statements
This press release
contains certain “forward-looking statements” as defined by the
Private Securities Litigation Reform Act of 1995 which represent
management’s beliefs and assumptions concerning future events.
These forward-looking statements are often indicated by using words
such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,”
“believes,” or plans, and may include statements regarding
corporate objectives as well as the attainment of certain corporate
goals and milestones. Forward-looking statements are based on
present circumstances and on management’s present beliefs with
respect to events that have not occurred, that may not occur, or
that may occur with different consequences or timing than those now
assumed or anticipated. Actual results may differ materially from
those expressed in forward looking statements due to
known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT
INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram:
@taurigum
Twitter:
@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce
Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024